Study #2016-0982
Phase II Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection, NEOSTAR/INDUCTION - Strategic Alliance: BMS
Study Status
Open
Treatment Agent
Cisplatin, Docetaxel, Ipilimumab, Nivolumab, Pemetrexed
Principal Investigator
Tina Cascone
Description
The goal of this clinical research study is to see which of these induction therapies works best when given to patients with non-small cell lung cancer (NSCLC) that can be surgically treated: nivolumab alone, nivolumab plus ipilumumab, and/or nivolumab plus platinum-based chemotherapy. The study drug combinations being tested in the study include (1) nivolumab, (2) nivolumab plus ipilumumab, and (3) nivolumab with platinum-based chemotherapy drugs (cisplatin, and either docetaxel or pemetrexed). Data from this study will be compared to data from patients who previously took induction platinum-based chemotherapy alone. Researchers want to learn how effective both study treatments may be in helping to control NSCLC after surgery.
General Information
Disease Group: Malignant neoplasms of respiratory and intrathoracic organs
Treatment Agent: Cisplatin, Docetaxel, Ipilimumab, Nivolumab, Pemetrexed
Treatment Location: Only at MD Anderson
Sponsor: Strategic Alliance: Bristol Myers Squibb (supporter)
Study Status
IRB Review and Approval Date: 06/09/2017
Recruitment Status: Open
Projected Accrual: N/A
Resources and Links
Information and next steps
Disease:
Malignant neoplasms of respiratory and intrathoracic organs
Study phase:
Phase II
Physician name:
Tina Cascone
Department:
Thoracic and Head and Neck Med
For general questions about clinical trials:
1-877-632-6789